NEW YORK (GenomeWeb News) – Myriad Genetics announced after the close of the market on Thursday an agreement with Pharma Mar to conduct BRCA1 and BRCA2 testing on patients enrolled in a clinical study for the drug firm's novel drug candidate.

Under the agreement, Myriad will conduct testing for patients in a Phase II clinical study for Pharma Mar's PM1183 drug candidate, which induces double-stranded DNA break to cause cell death. Myriad will evaluate BRCA status in patients who respond to the drug candidate.

Financial and other terms were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.